SEC Form 10-Q filed by Aclaris Therapeutics Inc.
$ACRS
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/23/2024 | $20.00 | Neutral → Buy | H.C. Wainwright |
| 11/20/2024 | Neutral → Overweight | Cantor Fitzgerald | |
| 11/19/2024 | $2.00 → $7.00 | Market Perform → Outperform | Leerink Partners |
| 11/19/2024 | $8.00 | Neutral → Buy | BTIG Research |
| 11/19/2024 | $2.00 → $7.00 | Hold → Buy | Jefferies |
| 11/18/2024 | $3.00 → $13.00 | Neutral → Overweight | Piper Sandler |
| 1/22/2024 | Buy → Neutral | H.C. Wainwright | |
| 11/13/2023 | Outperform → Mkt Perform | William Blair |
WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS) (the "Company" or "Aclaris"), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective January 2, 2025, the Compensation Committee of Aclaris' Board of Directors (the Committee) granted nonstatutory stock options to purchase an aggregate of 215,000 shares of its common stock and 61,000 restricted stock units to 1 new employee under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the "2024 Inducement Plan"). The stock options and restricted stock units were granted as inducements material to the new employ
WAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS)(the "Company" or "Aclaris"), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective December 2, 2024, the Compensation Committee of Aclaris' Board of Directors (the "Committee") granted nonstatutory stock options to purchase an aggregate of 251,000 shares of its common stock and 73,000 restricted stock units to 4 new employees under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the "2024 Inducement Plan"). In addition, also effective December 2, 2024, the Committee granted Hugh Davis, Ph.D, Aclaris' ne
WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 1:00 PM ET in New York, New York. A webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris' website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website. About Aclaris Therapeutics, Inc. Aclaris Therapeuti
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
H.C. Wainwright upgraded Aclaris Therapeutics from Neutral to Buy and set a new price target of $20.00
Cantor Fitzgerald upgraded Aclaris Therapeutics from Neutral to Overweight
Leerink Partners upgraded Aclaris Therapeutics from Market Perform to Outperform and set a new price target of $7.00 from $2.00 previously
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)
CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.
- Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board of Directors - Kevin Balthaser appointed Chief Financial Officer to succeed retiring Frank Ruffo - Matthew Rothman appointed General Counsel WAYNE, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced several key leadership changes. Effective January 1, 2023, co-founder
WAYNE, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has appointed Robert A. Doody Jr. as Vice President, Investor Relations. "We are very excited that we continue further strengthening our team through the addition of experienced industry veterans with successful track records," said Neal Walker, Chief Executive Officer of Aclaris. "Bob brings to Aclaris considerable experience leading investor relations programs across a number of various therapeutic sectors." Mr. Doody has nearly 20 years of biotechnology i
- Enhances Aclaris' pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-cl
– First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced;Top-line Data Anticipated in First Half of 2025 – WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2024 and provided a corporate update. "The third quarter of 2024 marked an important milestone for Aclaris with the dosing of our first patient in the Phase 2a trial of ATI-2138 for moderate to severe atopic dermatitis," said Dr. Neal Walker, Interim President & CEO and Chair of
-Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million- WAYNE, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2024 and provided a corporate update. "With study activities underway for our ATI-2138 Phase 2a trial in moderate to severe atopic dermatitis and the strengthening of our balance sheet through the completion of our royalty purchase agreement wi
8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)
EFFECT - Aclaris Therapeutics, Inc. (0001557746) (Filer)
424B3 - Aclaris Therapeutics, Inc. (0001557746) (Filer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)
4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)